High levels of IGF-1R can cause resistance across different cancers [72, 82], and cancer cells can become resistant to IGF-1R inhibitors, by activating PI3K/mTOR pathways through alternative EGFR signaling [83, 84]. This evidence concerns the gene EGFR and cancer.